Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1β/IL-17A axis

Mucosal Immunology
C NingG-J Chen

Abstract

Colitis-associated colorectal cancer (CAC) is the most serious complication of inflammatory bowel disease (IBD). Excessive complement activation has been shown to be involved in the pathogenesis of IBD. However, its role in the development of CAC is largely unknown. Here, using a CAC model induced by combined administration of azoxymethane (AOM) and dextran sulfate sodium (DSS), we demonstrated that complement activation was required for CAC pathogenesis. Deficiency in key components of complement (e.g., C3, C5, or C5a receptor) rendered tumor repression in mice subjected to AOM/DSS. Mechanistic investigation revealed that complement ablation dramatically reduced proinflammatory cytokine interleukin (IL)-1β levels in the colonic tissues that was mainly produced by infiltrating neutrophils. IL-1β promoted colon carcinogenesis by eliciting IL-17 response in intestinal myeloid cells. Furthermore, complement-activation product C5a represented a potent inducer for IL-1β in neutrophil, accounting for downregulation of IL-1β levels in the employed complement-deficient mice. Overall, our study proposes a protumorigenic role of complement in inflammation-related colorectal cancer and that the therapeutic strategies targeting complement ...Continue Reading

References

Oct 19, 2001·Proceedings of the National Academy of Sciences of the United States of America·B SiegmundC A Dinarello
Feb 8, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stephane FerrettiAlexandre Trifilieff
Aug 5, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ren-Feng GuoPeter A Ward
Nov 11, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Trent M WoodruffStephen M Taylor
Mar 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Feng LinM Edward Medof
Jun 15, 2004·American Journal of Physiology. Gastrointestinal and Liver Physiology·Steven H Itzkowitz, Xianyang Yio
Oct 16, 2004·Immunity·Jay K Kolls, Anders Lindén
Feb 3, 2006·Proceedings of the National Academy of Sciences of the United States of America·Miho NozakiJayakrishna Ambati
Apr 5, 2007·Nature Protocols·Stefan WirtzMarkus F Neurath
Jul 25, 2008·Nature·Alberto MantovaniFrances Balkwill
Sep 30, 2008·Nature Immunology·Maciej M MarkiewskiJohn D Lambris
Apr 7, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Priya D A IssureeAlirio J Melendez
Mar 27, 2010·American Journal of Physiology. Gastrointestinal and Liver Physiology·Fengxin LuAlvin E Davis
Dec 29, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Markus BosmannPeter A Ward
Feb 1, 2012·The Journal of Experimental Medicine·Michael H ShawGabriel Núñez
Feb 23, 2012·Carcinogenesis·Yil Sik HyunHo-Youn Kim
Apr 13, 2012·American Journal of Physiology. Cell Physiology·Qi CaoAndrew W Stadnyk
Oct 3, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Leticia CorralesRuben Pio
Apr 5, 2013·Neoplasia : an International Journal for Oncology Research·Isaiah Gregory SchauerJinsong Liu
Apr 17, 2013·The Journal of Experimental Medicine·Stefanie KirchbergerFiona Powrie
Jul 16, 2014·The Journal of Experimental Medicine·Randy S LongmanDan R Littman

❮ Previous
Next ❯

Citations

May 18, 2016·Trends in Molecular Medicine·Elena MagriniCecilia Garlanda
Nov 17, 2017·Nature Immunology·George HajishengallisJohn D Lambris
Sep 19, 2017·Nature Reviews. Immunology·Edimara S ReisJohn D Lambris
Dec 30, 2016·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Sojoong ChoiEok-Soo Oh
Oct 13, 2015·Oncotarget·Eduardo BonavitaCecilia Garlanda
Oct 27, 2016·Immunological Reviews·Pedro BerraondoRuben Pio
Mar 8, 2019·Nature Reviews. Cancer·Rajendra Karki, Thirumala-Devi Kanneganti
Nov 16, 2016·Evidence-based Complementary and Alternative Medicine : ECAM·Changming LiuJicheng Li
Aug 31, 2016·International Journal of Oncology·Xu ZhangWenrong Xu
Dec 5, 2018·Signal Transduction and Targeted Therapy·Yuhui WuWeidong Han
Mar 17, 2018·The British Journal of Radiology·Monica M OlcinaAmato J Giaccia
Mar 30, 2018·Frontiers in Oncology·Ashleigh R Poh, Matthias Ernst
Sep 13, 2018·Mammalian Genome : Official Journal of the International Mammalian Genome Society·Agampodi Promoda PereraHeinrich Körner
Dec 4, 2019·Cancer Cell International·Ronghua ZhangYupei Zhao
Aug 21, 2020·Life Science Alliance·Nazia AbbasiWendy Jia Men Huang
Jul 9, 2020·Cancers·Cédric Rébé, François Ghiringhelli
Oct 17, 2019·Genes·Monika StastnaVladimir Korinek
Apr 26, 2019·Frontiers in Immunology·Andrea DoniBarbara Bottazzi
Aug 19, 2016·Molecular Cancer Research : MCR·Stephanie K DoernerJoseph H Nadeau
Mar 10, 2021·NPJ Precision Oncology·Jeong-Hoon JangYoung-Joon Surh
Mar 12, 2021·Frontiers in Cellular and Infection Microbiology·Patricia M SikorskiMichael E Grigg
Apr 4, 2021·Cancers·Rebecca M O'BrienNiamh Lynam-Lennon
Sep 10, 2020·Endocrine, Metabolic & Immune Disorders Drug Targets·Sridhar MuthusamiIlangovan Ramachandran

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.